Vitiligo

Ruxolitinib cream 1.5% may soon be the first FDA-approved treatment for repigmentation of vitiligo. Experts share what dermatologists need to know regarding efficacy, safety, and cost of this topical drug.

In this drug pipeline video, Pearl Grimes, MD, FAAD, and Seemal R. Desai, MD, FAAD discuss what's currently happening in the vitiligo pipeline including why current treatments are lacking, what's coming soon, and what it may cost.

Vitiligo is challenging to treat; fortunately, continued research has led to improvements and refinements in options, giving much-needed hope to patients with this skin condition.

VYNE Therapeutics announced positive preclinical data of a lead BET inhibitor reducing melanocyte loss and key inflammatory biomarkers from an ex vivo skin model of vitiligo.

Long underserved by a narrow armamentarium, patients with pigmentary disorders could soon see a new wave of oral and topical solutions to treat even the most challenging cases.

This episode of The Cutaneous Connection podcast, sponsored by Incyte, explores the world of vitiligo. From symptoms to current treatment dissatisfaction and the latest research, Pearl Grimes, MD, FAAD, explains where we are now with this pigmentary disorder and where we are headed.

Ruxolitinib cream (Opzelura; Incyte) receives priority review of its supplemental New Drug Application as a treatment for patients with vitiligo.

Looking toward the future management of vitiligo, expert dermatologists close out their discussion on JAK inhibition and other novel therapy.

Shared insight from dermatologists on novel topical JAK inhibitor therapy being investigated as an option for patients with vitiligo.

A recent study examined the impact of virtual group visits to obtain community and education for pediatric vitiligo and alopecia areata patients and caregivers.

A brief review of the treatment armamentarium for vitiligo, as well as the prevalent unmet needs in that setting.

A recent JAAD study evaluated the correlation between F-VASI and T-VASI using patient- and physician-reported measures of clinical improvement, PaGIC-V and PhGVA.

Seemal Desai, MD, FAAD, and William Damsky, MD, PhD, discuss methods for managing a patient’s motivation and expectations when on therapy for vitiligo.

In this video interview, James Q Del Rosso, DO, tackles the clinical impact of JAK Inhibitors and how to deal with patient concern.

Expert perspectives on the diagnosis of vitiligo and considerations for improving provider awareness in dermatologist and community settings.

A comprehensive breakdown of the different classifications of vitiligo and how these may present clinically.

In this exclusive video interview, James Q Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the headlines around the treatments.

Shared insight on the psychological and social impact of vitiligo, along with practical advice on how to communicate with and support patients.

Expert dermatologists Seemal Desai, MD, FAAD, and William Damsky, MD, PhD, provide an overview of vitiligo, as an autoimmune disorder, and its prevalence.

The potential of JAK inhibitors and other emerging medications could answer demand for more treatment options for these challenging skin conditions. Read down below.

Ruxolitinib meets primary and secondary endpoints in phase 3 TRuE-V clinical trial program.

Investigators reported that patients in the vitiligo group reported worse general health, and were willing to pay more than 40% of their income for a cure.

A recent study evaluated the efficacy of the patient reported outcome measure instrument Clinical Evolution-Vitiligo for scoring nonsegmental vitiligo.

A study in the Journal of the American Academy of Dermatology investigated the maintenance of results of ruxolitinib cream in patients with vitiligo.

Incyte announced that ruxolitinib cream has received validation for its European marketing authorization application from the European Medicines Agency.